Related Experiment Videos
Norbornyllactone-substituted xanthines as adenosine A(1) receptor antagonists
William F Kiesman1, Jin Zhao, Patrick R Conlon
1Department of Medicinal Chemistry, Biogen Idec, Inc., 14 Cambridge Center, Cambridge, MA 02142, USA. william.kiesman@biogenidec.com
Bioorganic & Medicinal Chemistry
|February 7, 2006
Summary
Researchers developed novel xanthine compounds as potential alternatives to BG9719 for adenosine A(1) receptor antagonism. These new molecules exhibit strong binding affinities and in vivo activity, offering promising therapeutic options.
Area of Science:
- Medicinal Chemistry
- Pharmacology
Background:
- Adenosine A(1) receptors play crucial roles in various physiological processes.
- Development of selective antagonists is important for therapeutic applications.
- BG9719 is a clinical candidate for adenosine A(1) receptor antagonism.
Purpose of the Study:
- To discover novel second-generation adenosine A(1) receptor antagonist alternatives to BG9719.
- To synthesize and characterize new xanthine derivatives with norbornyl-lactone substituents.
Main Methods:
- Chemical synthesis of novel xanthine compounds.
- In vitro binding assays to determine receptor affinity.
- In vivo studies to evaluate pharmacological activity.
Main Results:
- A series of novel xanthines substituted with norbornyl-lactones were successfully developed.
- These compounds demonstrated high binding affinities for adenosine A(1) receptors.
- The novel xanthines exhibited significant in vivo activity.
Conclusions:
- The novel xanthine derivatives represent promising candidates for adenosine A(1) receptor antagonism.
- These findings provide a foundation for further development of these compounds as therapeutic agents.